Publication
New rules for MDEL holders: Health Canada’s terms and conditions authority
Amendments to the Medical Devices Regulations affecting the regulatory framework for medical device establishment licences (MDEL) are now in effect.
Author:
Canada | Publication | August 12, 2021
The Canadian Securities Administrators (CSA) have proposed a new prospectus exemption for issuers listed on a Canadian stock exchange wishing to raise equity capital (the Listed Issuer Financing Exemption). The exemption will take effect by amendment of National Instrument 45-106 Prospectus Exemptions and is part of the CSA’s ongoing efforts to reduce the regulatory burden for non-investment fund reporting issuers, including providing efficient means for issuers to raise capital while maintaining investor protection. This new exemption will not require preparing a short-form prospectus, thereby reducing time and costs, and will be of particular interest to smaller issuers looking for an alternative offering model. The Listed Issuer Financing Exemption is focused on a reporting issuer’s continuous disclosure record. Comments on the proposed exemption should be submitted by October 26, 2021.
The Listed Issuer Financing Exemption proposes a more efficient method for smaller listed issuers to raise equity capital. Public commentary received and the CSA’s research indicated that the cost of the current short-form prospectus system can be prohibitive and dealers have less interest in smaller offerings. The Listed Issuer Financing Exemption is aimed at reducing issuer costs, facilitating retail investor participation, providing investors with better and more current disclosure than in a private placement and providing incentive for issuers to access public markets.
To rely on the exemption, an issuer:
In addition, the exemption places the following limitations on the amounts that may be raised:
The proceeds of funds raised under the Listed Issuer Financing Exemption may not be used for a significant acquisition or restructuring transaction that would require additional financial statements under the prospectus rules or for any other transaction that requires approval of any security holder.
Securities distributed under the exemption must be a listed equity security, a unit consisting of a listed equity security and a warrant, or a security convertible into a listed equity security or a unit consisting of a listed equity security and a warrant. The CSA is of the view that listed equity securities are easier for investors to understand and such securities have a market valuation. The exemption may be used for money raised in a subscription receipt transaction, provided shareholder approval of the transaction is not required. The CSA has solicited public comments as to whether convertible debt should be included as an equity security as currently drafted.
To rely upon the Listed Issuer Financing Exemption, there is no requirement for a registrant or underwriter to be retained in connection with the offering. Investment dealers and exempt market dealers that are involved will be subject to their registration requirements. For example, dealers placing the stock with their clients will need to satisfy their client obligations in order to ensure the investment is suitable (KYC / KYP requirements).
The issuer must announce the offering by press release before soliciting an offer to purchase the securities. The issuer must state that the offering document is accessible on SEDAR+ and on the issuer’s website.
A listed issuer must prepare a Listed Issuer Financing Document in the form prescribed by NI 45-106. The CSA does not expect it to be longer than a few pages. The offering document will need to include the following information in a Q and A format (and in plain language or, in certain instances, as prescribed):
The financing document must be filed on SEDAR+ and posted on an issuer’s website before soliciting a purchaser. It must also be filed with the relevant securities regulators before soliciting a purchase and no later than three business days after the date of the form. The document (together with the continuous disclosure documents) must disclose all material facts about the issuer and its securities and must not contain a misrepresentation. It must be in French or French and English for use in Quebec. The distribution must end no later than the 45th day after issuing the news release.
To allow CSA members to collect data on the offerings, a Form 45-106 F1: Report of Exempt Distributions must be filed within 10 days of the distribution of securities. However, detailed confidential information on the purchasers is not required (Schedule 1).
Equity securities issued in reliance on the exemption will be freely tradeable but subject to a seasoning period that will be satisfied by the issuer being a reporting issuer in good standing.
Purchasers under the exemption will have the same rights as purchasers in the secondary market regarding misrepresentations contained in the short offering document and 12-month continuous disclosure record. In addition, purchasers under the exemption will also have a right to rescind the purchase within a period of 180 days from purchase.
The CSA has specifically requested comments on the following topics, among others:
The full text of the amendments is available here.
Publication
Amendments to the Medical Devices Regulations affecting the regulatory framework for medical device establishment licences (MDEL) are now in effect.
Publication
Early January is a good time to take stock of workplace law developments that arose in 2024, and how those developments may evolve in 2025.
Publication
As you prepare for your next AGM, stay up-to-date on key developments in Canadian corporate and securities legislation, corporate governance guidance and institutional shareholder proxy voting guidelines that may impact the management information circular for your 2025 annual shareholder meeting and your 2025 annual disclosure filings.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025